Therapeutic Solutions International Inc (TSOI)

[centsability4me]

TSOI PR history from 5/1 to 9/4
with the most recent PR on top :


NEWS : 9/4/18
https://ih.advfn.com/p.php?pid=nmona&article=78186786

Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access
of its StemVacs Product for American Cancer Patients

Company to use Phase I Data of its Cancer Stem Cell Immunotherapy to Allow for use in the USA under President Donald Trump's
Right to Try Law

Oceanside, CA -- September 04, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today completion of a Phase I clinical trial in advanced cancer patients using its StemVacs cellular immunotherapy. The clinical trial was aimed at establishing the safety of StemVacs, an immunotherapeutic cell-based drug that instructs the immune system to seek and destroy cancer stem cells. It is believed that cancer stem cells are responsible for initiating the growth of tumors.

"Through our collaborators at the Pan Am Cancer Treatment Centers, we have been able to successfully administer the StemVacs cellular cancer immunotherapeutic to 10 patients with various types of advanced cancers. We have observed no treatment-associated adverse events, and in some cases, stabilization of tumors and stimulation of immunity were observed and noted" said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "This Phase I safety data strongly supports our continued clinical development of StemVacs, of which part of the development pathway includes providing patients access to it now under the Right to Try Law."

Dendritic cells (DC), which are the main ingredient in StemVacs, are cells of the immune system whose primary function is to initiate immune responses against different pathogens (1,2). In the context of cancer, DC's activate immune responses that in some cases are capable of killing cancer cells (3,4). Unfortunately, in cancer patients, many times the dendritic cells are not functionally active (5-7). This is because cancer cells produce factors such as VEGF, which inhibit the ability of the DC to perform their job of activating T cells (8,9). The StemVacs product is comprised of DC that are generated under laboratory conditions so as to render them resistant to the inhibitory effects of cancer. Additionally, the StemVacs DC's are designed so as to induce an immune response against cancer stem cells.

"Immunotherapy is the greatest advancement in the area of clinical oncology. FDA approved immunotherapies include the DC based product Provenge, the T cell based products Yescarta and Kymriah, and antibody based therapies such as Opdivo and Keytruda" said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "To our knowledge, StemVacs is the only clinical stage immunotherapeutic that kills cancer stem cells. This, combined with the safety and signals of efficacy obtained from the current Phase I clinical trial, support us to expand the use of StemVacs under President Trump's recently passed Right to Try Law."

NEWS : 8/22/18
https://ih.advfn.com/p.php?pid=nmona&article=78119448

Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Players
Company to Advance NeuroStilbene Product for High-Performance Athletes
Susceptible to Head Injuries

NEWS : 8/13/18
https://ih.advfn.com/p.php?pid=nmona&article=78060284

Therapeutic Solutions International Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene
Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline

NEWS : 8/6/18
https://ih.advfn.com/p.php?pid=nmona&article=78013140

Therapeutic Solutions International Develops Microemulsion Formulation of
Alpha Lipoic Acid for Intranasal Delivery

Company Expands Product Pipeline in Neurodegenerative Arena

NEWS : 7/23/18
https://ih.advfn.com/p.php?pid=nmona&article=77913150

Therapeutic Solutions International Recruits Internationally Recognized Cancer Immunotherapy Pioneer Dr. Francesco Marincola to Accelerate StemVacs and NanoStilbene Clinical Development
Company Focuses on Non-Toxic Therapies Using Immune System
to Selectively Kill Cancer Cells through Immunotherapy

NEWS : 7/16/18
https://ih.advfn.com/p.php?pid=nmona&article=77868683
Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene for
Rapid Access to Blood-Brain Barrier
Company Expands its Pterostilbene Based Portfolio into Brain Cancers
Oceanside, CA -- July 16, 2018 -- Investorshub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the release of NeuroStilbene, a proprietary nano-formulation of pterostilbene formulated for intranasal delivery.

NEWS : 7/9/18
https://ih.advfn.com/p.php?pid=nmona&article=77825316
Therapeutic Solutions International, Inc., Appoints Juergen Winkler, MD, ABIHM to Scientific Advisory Board
Pioneer of Functional Medicine Teams Up with Clinical Stage Biotechnology Company in Commercialization of Non-Toxic Immunotherapy

NEWS : 7/2/18
https://ih.advfn.com/p.php?pid=nmona&article=77784227
Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbene™
Early Clinical Trial Data Supports Enhanced Biodistribution of NanoStilbene™ Compared to Standard Pterostilbene When Orally Administered

NEWS : 6/25/18
https://ih.advfn.com/p.php?pid=nmona&article=77734511
Therapeutic Solutions International Releases "IsoStilbene" Injectable Formulation of Pterostilbene Under Granted Patent for Augmentation of Immunotherapy and Targeting of Cancer Stem CellsIsoStilbene to be Included in Pan American Cancer Treatment Center Protocols

NEWS : 6/18/18
https://ih.advfn.com/p.php?pid=nmona&article=77684969
Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer

Oceanside, CA -- June 18, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) previously announced their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by President Trump on May 30th 2018, and have appointed Dr. James Veltmeyer as Chief Medical Officer of their future planned cancer clinic.

NEWS : 6/11/18
ih.advfn.com/p.php?pid=nmona&article=77635806
Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of "Universal Cancer Antigen" into StemVacs Dendritic Cell Platform

OCEANSIDE, CA -- June 11, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today initiation of efforts to combine its existing CTCFL "universal cancer antigen", labeled as BRS-001, with its clinical stage StemVacs Dendritic Cell Platform.

BORIS Info:
http://stemvacs.com/?page_id=145

NEWS : 6/6/18
http://ih.advfn.com/p.php?pid=nmona&article=77606645
Therapeutic Solutions International Announces Licensing of Additional Technologies to
Pan American Cancer Treatment Center

Patent Title: Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants : Cancer Metabolic DeTox
http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-targeting-tumor-microenvironment-through-nutraceutical-otc-pink-tsoi-2215015.htm
Patent Title: Methods of Re-Activating Dormant Memory Cells with Anticancer Activity : MemoryMune
http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-methods-re-activating-dormant-memory-cells-with-otc-pink-tsoi-2220094.htm
Patent Title: Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization : StemVacs
http://www.marketwired.com/press-release/therapeutic-solutions-international-announces-filing-new-immunotherapy-patent-exclusive-otc-pink-tsoi-2208787.htm
Patent Title:Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof : LymphoBoost
http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-augmentation-anti-tumor-immunity-mifepristone-otc-pink-tsoi-2217703.htm
Patent Title: Activated Leukocyte Extract for Repair of Innate Immunity in Cancer Patients : innaMune
http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-blood-derived-innate-immune-system-stimulator-otc-pink-tsoi-2216672.htm

Pan Am Cancer Treatment Center
Telephone: [phone]
Diego Rivera #2339 suite 108
Zona Rio, Tijuana B.C. 22010
www.cancerimmunotherapy.mx
[e-mail]
Pan Am Cancer Treatment Center Intoductory video :
https://www.youtube.com/watch?v=rWgJLRCICa8&feature=youtu.be

NEWS : 5/31/18
http://ih.advfn.com/p.php?pid=nmona&article=77561606
Therapeutic Solutions International to Provide Patients Access to StemVacs Cancer Immunotherapy through Newly Passed Right to Try Law

NEWS : 5/21/18
http://ih.advfn.com/p.php?pid=nmona&article=77477228
Therapeutic Solutions International Releases "DermalStilbene" a Topical Formulation of Pterostilbene

NEWS : 5/15/18
http://ih.advfn.com/p.php?pid=nmona&article=77431704
Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant Nanostilbene

NEWS : 5/9/18
http://ih.advfn.com/p.php?pid=nmona&article=77382606
Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board
Company to Iniate Investigational Cardiovascular Study with Dr. Azimi and Nanostilbene

NEWS : 5/1/18
http://ih.advfn.com/p.php?pid=nmona&article=77309980
Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment
Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with
Patented Augmenter of Cancer Immunotherapy NanoStilbene